Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

AGM Statement

27 May 2015 07:00

RNS Number : 2898O
Cambridge Cognition Holdings PLC
27 May 2015
Β 

Β 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Β 

AGM Statement

Β 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

Β 

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

Β 

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

Β 

The contribution from our clinical trials and academic businesses continued to grow in the first quarter. In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

Β 

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

Β 

Β 

Enquiries:

Β 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

Β 

Β 

Β 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

Β Β Β 

Β 

Β 

Β 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.Β The company's range of touch-screen CANTABβ„’ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enablingΒ health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
AGMPKADPABKDAPB
Date   Source Headline
14th Nov 20187:00 amRNSContract win in growing eCOA revenue stream
20th Sep 20187:00 amRNSHalf Yearly Report
19th Sep 20187:00 amRNSCompany signs first NeuroVocalix contract
13th Sep 20187:00 amRNSNeuroVocalixT platform ready for clinical trials
1st Aug 20187:00 amRNSCANTAB incorporated in population health platform
20th Jun 20187:00 amRNSNew product to improve workplace mental health
7th Jun 20187:00 amRNSPartnership to tackle growing mental health need
31st May 20187:00 amRNSNew client signs with Cognition Kit software
24th May 201812:24 pmRNSResult of AGM
9th May 201811:34 amRNSHolding(s) in Company
3rd May 20187:00 amRNSDirector/PDMR Shareholding
2nd May 20187:00 amRNSPosting of Annual Report & Notice of AGM
12th Apr 20181:20 pmRNSHolding(s) in Company
12th Apr 201810:20 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSRecruitment contracts show strong growth
26th Mar 20187:00 amRNSMajor Contract Win and Funding Award
22nd Mar 201811:05 amRNSSecond Price Monitoring Extn
22nd Mar 201811:00 amRNSPrice Monitoring Extension
22nd Mar 20187:00 amRNSFinal Results
1st Mar 20187:30 amRNSHolding(s) in Company
27th Feb 20184:25 pmRNSHolding(s) in Company
10th Jan 20187:00 amRNSTrading Update and Notice of Results
5th Dec 20178:55 amRNSHolding(s) in Company
28th Nov 20177:00 amRNSWearable technology demonstrates high compliance
2nd Nov 20177:00 amRNSGrant of Options
10th Oct 201711:00 amRNSHolding(s) in Company
10th Oct 201710:58 amRNSHolding(s) in Company
6th Oct 20177:00 amRNSIssue of Equity
21st Sep 20177:00 amRNSHalf-year Report
12th Sep 20177:00 amRNSAward of Funding
31st Aug 20177:00 amRNSNotice of Results
12th Jun 20179:56 amRNSHolding(s) in Company
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
7th Jun 20177:00 amRNSSpeech recognition for clinical trials
25th May 20172:22 pmRNSResult of AGM & Board Change
24th May 20174:27 pmRNSHolding(s) in Company
22nd May 20177:00 amRNSIssue of Equity
11th May 20171:07 pmRNSHolding(s) in Company
10th May 20177:00 amRNSGrant of Options
2nd May 20177:00 amRNSPosting of Annual Report & Notice of AGM
30th Mar 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSAnnual Financial Report
16th Mar 20177:00 amRNSCANTAB used in EBBINGHAUS cognitive function trial
7th Mar 20177:00 amRNSLaunch of web-based testing for virtual research
24th Feb 20177:00 amRNSPartnership With Takeda For Wearables
23rd Feb 20177:00 amRNSNotice of Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUS regulatory clearance for CANTAB Mobile
4th Nov 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSContract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.